Part 4: New ICD-10 Codes and IPPS Changes
Pat Maccariella‑Hafey
RHIA, CDIP, CCS, CCS‑P, CIRCC
Executive Director Of Education
AHIMA‑Approved ICD‑10‑CM/PCS Trainer and Ambassador
New Technology Add-On Payments (NTAP) FY2020
In the previous three parts of this four part series, we discussed the new ICD-10-CM diagnosis code changes, ICD-10-PCS procedure code changes and FY2020 IPPS changes. In this last Part 4 of the series, we will review the NTAP procedure codes and reimbursement add-on payments for FY2020.
Section “X” New Technology
CMS provides incremental payment (in addition to the DRG payment) for technologies that qualify for NTAP. FY2020 65% up from 50%. The agency finalized a 75% new technology add-on payment for certain antimicrobials.
Section “X” is a separate place within ICD-10-PCS for certain new technology procedures (such as new technology drugs). Section “X” does not introduce any new coding concepts or unusual guidelines for correct coding and maintains continuity with the other sections in ICD-10-PCS. The same root operation and body part values are used in section “X” as in other sections. The seventh character in section “X” is used to indicate the new technology group. This is a number or letter that changes each year that new technology codes are added. It is only used to indicate the year the code was created and all codes for that update year will have the same qualifier. The new technology drugs for FY2019 will have the qualifier/seventh character of “4” since this is the third year of ICD-10-PCS.
Section “X” codes are standalone codes. No additional codes from other sections in ICD-10-PCS are necessary for reporting as the specific procedure is described in the code title from section “X”.
New Technology section codes are easily found by looking in the ICD-10-PCS Index or the Tables. The name of the new technology device, substance or technology for a section “X” code is included as the main term. They are also listed under the main term “New Technology”.
New technology items have a new technology payment that is made in addition to the DRG payment for hospital inpatients. Missing new technology codes is a frequent error made by coders. Coders must familiarize themselves with the new technologies of each year.
CMS Website Information on New Technology: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html
EVERY CODE COUNTS!
New Technology Procedure Codes and Reimbursement for FY2020
Below are the codes that will be reimbursed as NTAP codes. You may want to print this out and keep it handy or on your desktop for future reference.
1. YESCARTA™ (Axicabtagene Ciloleucel)
and KYMRIAH™ (Tisagenlecleucel). (Fights non-Hodgkin’s Lymphoma and Acute Lymphoblastic Leukemia) For these CAR T-Cell therapies, the cost is $373,000. The maximum payment a hospital can receive for this is $242,450 as a new technology add on payment.
- XW033C3 – Introduction of engineered autologous chimeric antigen receptor t-cell immunotherapy intoperipheral vein, percutaneous approach, new technology group 3
- XW043C3 – Introduction of engineered autologous chimeric antigen receptor t-cell immunotherapy intocentral vein, percutaneous approach, new technology group 3
2. VYXEOS™ intravenous for treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The maximum payment a hospital can receive for this is $47,352.50 as a new technology add on payment.
- XW033B3 – Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into peripheral vein, percutaneous approach, new technology group 3
- XW043B3 – Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into central vein, percutaneous approach, new technology group 3
3. Remedē® System by Respicardia, Inc. is indicated for use as a transvenous phrenic nerve stimulator in the treatment of adult patients who have been diagnosed with moderate to severe central sleep apnea (CSA). The Remedē® System consists of an implantable pulse generator, and a stimulation and sensing lead. The pulse generator is placed under the skin, in either the right or left side of the chest, and it functions to monitor the patient’s respiratory signals. A transvenous lead for unilateral stimulation of the phrenic nerve is placed either in the left pericardiophrenic vein or the right brachiocephalic vein, and a second lead to sense respiration is placed in the azygos vein. Both leads, in combination with the pulse generator, function to sense respiration and, when appropriate, generate an electrical stimulation to the left or right phrenic nerve to restore regular breathing pattern The maximum payment a hospital can receive for this is $22,425 as a new technology add on payment.
- 0JH60DZ – Insertion of Stimulator, Generator, Multiple Array into Subcutaneous Tissue, open approach
AND - 05H3/43MZ – Insertion of neurostimulator lead into right/left innominate vein, percutaneous
WITH - 05H03MZ – Insertion of neurostimulator lead into AZYGOS vein, percutaneous
OR - 05H04MZ – Insertion of neurostimulator lead into AZYGOS vein, percutaneous, endoscopic
4. ZEMDRI™(Plazonmicin). Next generation aminoglycoside antibiotic to treat multi-drug resistant gram-negative bacteria. Usually complicated UTI (cUTI) or pyelonephritis. The maximum payment a hospital can receive for this is $4,083.75 as a new technology add on payment.
- XW033G4 – Introduction of Plazomicin Anti-Infective into peripheral vein, percutaneous, new technology group 4
- XW043G4 – Introduction of Plazomicin Anti-Infective into central vein, percutaneous, new technology group 4
5. GIAPREZA™ a synthetic human angiotensin II, is administered through IV infusion to raise blood pressure in adult patients who have been diagnosed with septic or other distributive shock. The maximum payment a hospital can receive for this is $4,083.75 as a new technology add on payment.
- XW033H4 – Introduction of Synthetic Human Angiotensin II into peripheral vein, percutaneous, new technology group 4
- XW043H4 – Introduction of Synthetic Human Angiotensin II into central vein, percutaneous, new technology group 4
6. Cerebral Protection System (Sentinel® Cerebral Protection System). indicated for the use as an embolic protection (EP) device to capture and remove thrombus and debris while performing transcatheter aortic valve replacement (TAVR) procedures for aortic stenosis. Cases involving the use of the Sentinel® Cerebral Protection System that are eligible for new technology add-on payments will be identified by ICD–10–PCS procedure. The maximum payment a hospital can receive for this is $1,820 as a new technology add on payment.
- X2A5312 – Assistance via Innominate Artery and Left Common Carotid artery, percutaneous, Cerebral Embolic Filtration, Dual Filter, new technology group 2
7. VABOMERE™ (meropenem-vaborbactam) IV for adults with complicated UTIs and acute pyelonephritis (chills, rigors, temp higher than 38C, WBC over 10,000, etc.). The maximum payment a hospital can receive for this is $7,207.20 as a new technology add on payment.
- XW033N5 – Introduction of Meropenem-vaborbactam Anti-infective into peripheral vein, percutaneous, new technology group 5
- XW043N5 – Introduction of Meropenem-vaborbactam Anti-infective into central vein, percutaneous, new technology group 5
8. AQUABEAM System (Aquablation) is indicated for the use in the treatment of patients experiencing lower urinary tract symptoms caused by a diagnosis of benign prostatic hyperplasia (BPH). The AQUABEAM System consists of three main components: a console with two high-pressure pumps, a conformal surgical planning unit with transrectal ultrasound imaging, and a single-use robotic hand-piece. would be assigned. The maximum payment a hospital can receive for this is $1,625 as a new technology add on payment.
- XV508A4 – Destruction of prostate using robotic waterjet ablation, via natural or artificial opening endoscopic, new technology group 4
9. AndexXa™ (Andexanet alfa) is an antidote used to treat patients who are receiving treatment with an oral Factor Xa inhibitor who suffer a major bleeding episode and require urgent reversal of direct and indirect Factor Xa anticoagulation. Patients at high risk for thrombosis, including those who have been diagnosed with atrial fibrillation (AF) and venous thrombosis (VTE), typically receive treatment using long-term oral anticoagulation agents. The maximum payment a hospital can receive for this is $18,281.25 as a new technology add on payment.
- XW03372 – Introduction of Andexanet Alfa, Factor Xa Inhibitor Reversal agent into peripheral vein, percutaneous, new technology group 2
- XW04372 – Introduction of Andexanet Alfa, Factor Xa Inhibitor Reversal agent into central vein, percutaneous, new technology group 2
10. AZEDRA® (Ultratrace® iobenguane Iodine-131) is a drug solution for IV use in patients with obenguane avid malignant and/or recurrent and/or unresectable pheochroomocytoma and paraganglioma (PPGL). These are rare with incidence of 2-8 people per million per year. Paragangliomas have a malignancy frequency of 25%. They are both neuroendocrine tumors. The maximum payment a hospital can receive for this is $98,150 as a new technology add on payment.
- XW033S5 – Introduction of Iobenguane I-131 Antineoplastic into peripheral vein, percutaneous, new technology group 5
- XW043S5 – – Introduction of Iobenguane I-131 Antineoplastic into central vein, percutaneous, new technology group 5
11. CABLIVI® (caplacizumab-yhdp) is a humanized bivalent nanobody administered through IV and subcutaneous injections to inhibit micro clot formation in adult patients how have been diagnosed with thrombotic thrombocytopenic purpura (aTTP). The maximum payment a hospital can receive for this is $33,215 as a new technology add on payment.
- XW013W5 – Introduction of Caplacizumab into subcutaneous tissue, percutaneous, new technology group 5
- XW033W5 – Introduction of Caplacizumab into peripheral vein, percutaneous, new technology group 5
- XW043W5 – Introduction of Caplacizumab into central vein, percutaneous, new technology group 5
12. ELZONRIS™ is a targeted therapy for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) which is highly aggressive. Administered via infusion. The maximum payment a hospital can receive for this is $125,448.05 as a new technology add on payment.
- XW033Q5 – Introduction of Tagraxofusp-erzs Antineoplastic into peripheral vein, percutaneous, new technology group 5
- XW043Q5 – Introduction of Tagraxofusp-erzs Antineoplastic into central vein, percutaneous, new technology group 5
13. Balversa™ (Erdafitimib) indicated for the second-line treatment of adult patients who have been diagnosed with locally advanced or metastatic urothelial carcinoma whose tumors exhibit certain fibroblast growth factor receptor (FGFR) genetic alterations as detected by an FDA-approved test, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy. The maximum payment a hospital can receive for this is $3,563.23 as a new technology add on payment.
- XW0DXL5 – Introduction of Erdafitinib Antineoplastic into mouth and pharynx, external, new technology group 5
14. ERLEADA™ (Apalutamide). This oral drug is an androgen receptor inhibitor indicated for the treatment of patients who have been diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC). The maximum payment a hospital can receive for this is $1,858.25 as a new technology add on payment.
- XW0DXJ5- Introduction of Apalutamide Antineoplastic into mouth and pharynx, external, new technology group 5
15. SPRAVATO (Esketamine) is a nasal spray used for treatment-resistant (major) depression (TRD). The maximum payment a hospital can receive for this is $1,014.79 as a new technology add on payment.
- 3E097GC – Administration and introduction of other therapeutic substance, other substance into nose, via natural or artificial opening
16. XOSPATA® (gilteritinib). Is oral med indicated for the treatment of adult patients who have been diagnosed with relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. The maximum payment a hospital can receive for this is $7,312.50 as a new technology add on payment.
- XW0DXV5 – Introduction of Gilteritinib Antineoplastic into mouth and pharynx, external approach, new technology group 5
17. AKAFI™ (Ruxolitinib) JAKAFI™ is an oral kinase inhibitor that inhibits Janus-associated kinases 1 and 2 (JAK1/JAK2). The JAK pathway, which includes JAK1 and JAK2, is involved in the regulation of immune cell maturation and function. According to the applicant, JAK inhibition represents a novel therapeutic approach for the treatment of acute graft-versus-host disease (GVHD) in patients who have had an inadequate response to corticosteroids. The maximum payment a hospital can receive for this is $3,977.06. as a new technology add on payment.
- XW0DXT5 – Introduction of Ruxolitinib into mouth and pharynx, external approach, new technology group 5
18. T2Bacteria® Panel (T2 Bacteria Test Panel) Is a lab test indicated as an aid in the diagnosis of bacteremia, bacterial presence in the blood which is a precursor for sepsis. The maximum payment a hospital can receive for this is $97.50 as a new technology add on payment.
- XXE5XM5 – Measurement, circulatory, external, infection, whole blood nucleic acid-base microbial detection, new technology group 5
Happy Coding!
The information contained in this coding advice is valid at the time of posting. Viewers are encouraged to research subsequent official guidance in the areas associated with the topic as they can change rapidly.
Download 4-Part Series
Popular Posts
Coding Tip: Cardiac Arrest and Cardiac Shock
In the past, there had been an Excludes1 note at I46.- Cardiac arrest that excluded R57.0, Cardiac shock. HIA had also received a letter from AHA on a case in the past that had stated that only I46.- Cardiac arrest would be coded if both were documented. In addition, the Third Quarter Coding Clinic page 26 had a similar case that asked if both could be coded, and AHA had instructed that only I46.9, cardiac arrest, cause unspecified would be coded if both were documented and that the CDC would be looking at possible revision to the Excludes1 note.
Client X: Let’s Talk Numbers
A higher CMI corresponds to increased consumption of resources and increased cost of patient care, resulting in increased reimbursement to the facility from government and private payers, like CMS. We know that documentation directly impacts coding.
Coding Tip: Endarterectomy During Coronary Artery Bypass
Lately we have seen several cases where the endarterectomy was assigned along with the coronary artery bypass (CABG) procedure when being performed on the same vessel to facilitate the CABG. A coronary artery endarterectomy is not always performed during a CABG procedure, so when it is performed it becomes confusing as to whether to code it separately or not.
Coding Tip: Update – Coding COVID-19 When the Test is Negative
Assign code Z20.828, “Contact with and (suspected) exposure to other viral communicable diseases” for all patients who are tested for COVID-19 and the results are negative, regardless of symptoms, no symptoms, exposure or not as we are in a pandemic.
New ICD-10-PCS Procedure Codes for COVID-19
The Centers for Medicare & Medicaid Services (CMS) announced new procedure codes for treatments of COVID-19 – effective as of August 1, 2020. Among the new codes are Section X New Technology codes for the introduction or infusion of therapeutics including Remdesivir, Sarilumab, Tocilizumab, transfusion of convalescent plasma, as well as introduction of any other or new therapeutic substances for the treatment of COVID-19.
Subscribe to our weekly newsletter
Latest News
Coding Tip: Cardiac Arrest and Cardiac Shock
In the past, there had been an Excludes1 note at I46.- Cardiac arrest that excluded R57.0, Cardiac shock. HIA had also received a letter from AHA on a case in the past that had stated that only I46.- Cardiac arrest would be coded if both were documented. In addition, the Third Quarter Coding Clinic page 26 had a similar case that asked if both could be coded, and AHA had instructed that only I46.9, cardiac arrest, cause unspecified would be coded if both were documented and that the CDC would be looking at possible revision to the Excludes1 note.
Client X: Let’s Talk Numbers
A higher CMI corresponds to increased consumption of resources and increased cost of patient care, resulting in increased reimbursement to the facility from government and private payers, like CMS. We know that documentation directly impacts coding.
Coding Tip: Endarterectomy During Coronary Artery Bypass
Lately we have seen several cases where the endarterectomy was assigned along with the coronary artery bypass (CABG) procedure when being performed on the same vessel to facilitate the CABG. A coronary artery endarterectomy is not always performed during a CABG procedure, so when it is performed it becomes confusing as to whether to code it separately or not.
Coding Tip: Update – Coding COVID-19 When the Test is Negative
Assign code Z20.828, “Contact with and (suspected) exposure to other viral communicable diseases” for all patients who are tested for COVID-19 and the results are negative, regardless of symptoms, no symptoms, exposure or not as we are in a pandemic.
New ICD-10-PCS Procedure Codes for COVID-19
The Centers for Medicare & Medicaid Services (CMS) announced new procedure codes for treatments of COVID-19 – effective as of August 1, 2020. Among the new codes are Section X New Technology codes for the introduction or infusion of therapeutics including Remdesivir, Sarilumab, Tocilizumab, transfusion of convalescent plasma, as well as introduction of any other or new therapeutic substances for the treatment of COVID-19.
New Rule Helps Medicare ACOs During COVID-19 Pandemic
One common element in many value-based programs is risk adjustment using Hierarchical Condition Categories (HCCs) to create a Risk Adjustment Factor (RAF) score. This method ranks diagnoses into categories that represent conditions with similar cost patterns.
Part 5: Reasons for AKI Denials and Prevention | AKI Series
Why are so many AKI records being denied? It’s hard to give one answer for why so many AKI records are being denied lately, but most appear to be due to the multiple sets of criteria available for use in determining if a patient has AKI, as well as physician documentation. As stated in Part 3 of this series, there are three main criteria/classifications used to diagnose AKI.
Part 4: Is Documentation Present to Report Acute Kidney Injury/Failure? | AKI Series
In previous parts of this series we looked at the definitions of AKI/ARF, causes, coding and sequencing, and the common clinical indicators that patients present with that are diagnosed with this condition. In Part 4, we will look at the documentation that should be present to report the diagnosis without fear of denial, as well as when a query is needed to clarify the diagnosis.
Coding Tip: Z Code Reporting for COVID-19
If the facility does a COVID-19 test, and test is negative, do I need a diagnosis code. The answer is yes, you will report a Z-code. The Z-code depends on the record documentation and circumstances of testing. For any patient receiving a COVID-19 test, if negative, there MUST e a Z-code to describe why the test was taken. (Test negative for COVID-19 and MD does not override negative results).
Part 3: Clinical Indicators for Acute Kidney Injury/Failure | AKI Series
In the first parts of this series we looked at definitions of AKI/ARF, causes, coding and sequencing. In Part 3, we will look at what clinical indicators would possibly be present to support the diagnosis of AKI/ARF.
FY2021 Proposed Rule and Code Changes Highlights
The FY2021 IPPS Proposed Rule is out and here are some highlights from it regarding ICD-10 Code proposals. We will know if these changes are permanent after the public comment period is over on July 10, 2020 and CMS prepares the Final Rule, usually out by August 1.
Part 2: Specificity Coding of Acute Kidney Injury (AKI) and Sequencing | AKI Series
As discussed in Part 1 of this series, AKI/ARF is a common diagnosis that coders see daily. In Part 2, we are going to focus on the different types/specificity of AKI/ARF. We’ll learn what they mean, as well as how to code the diagnosis.
Part 1: What is Acute Kidney Injury (AKI)? | AKI Series
This is part 1 in a series focused on coding of acute kidney injury (AKI) and/or acute renal failure (ARF). AKI/ARF is reported often, but is also one of the most common diagnosis found in denials.
Coding Tip: Covid-19 Diagnosis Coding Common Scenarios
With the proliferation of COVID-19 cases, we thought we would put together a quick reference listing of some of the common scenarios that coders have asked about. As with all coding, coders should follow Official Guidelines for Coding and Reporting and the COVD-19 Frequently Asked Questions document by the AHA.
Reporting Telehealth Services During the COVID-19 Emergency
Effective March 1, Medicare will pay physicians for telehealth services at the same rate as in-person visits for all diagnoses, not just services related to COVID-19. This great for providers whose patients are reluctant to visit the office.
Coding Tip: What is Single Path Coding?
The biggest reasons why some hospital systems are moving to single path coding is to eliminate duplicative processes and to optimize productivity. In addition, costs are reduced when only one coder “touches” the record and completes both types of coding.
Coding Tip: Reporting Vaping in ICD-10-CM | Effective on 4/1/2020
Effective with 4/1/2020 discharges, ICD-10-CM code U07.0 is used to report vaping -related disorders. ICD-10-CM code U07.0 (vaping related disorder) should be used when documentation supports that the patient has a lung-related disorder from vaping. This code is found in the new ICD-10-CM Chapter 22. U07.0 will be in listed in the ICD-10-CM manual under a new section: Provisional assignment of new disease of uncertain etiology or emergency use.
Telehealth and the Coronavirus
The US government and public-health officials are urging consumers to utilize telemedicine for remote treatment, fill prescriptions and get medical attention during the new coronavirus pandemic. The goal is to keep people with symptoms at home and to practice social distancing if their condition doesn’t warrant more intensive hospital care.
Coronavirus: Tips for Working from Home
Coronavirus: Tips for working from home. Companies around the world have told their employees to stay home and work remotely. Whether you’re a new to this concept or a work from home veteran, here’s some tips to staying productive from our #HIAfamily.
Part 3: Coder and CDI Communication Example | CDI Series
This is the final part of a three part series in which we address how coders can better interact with Clinical Documentation Improvement (CDI) professionals. In this part, we provide an actual example of an effective communication response to CDI.
Part 2: How Coders Can Address Coding Mismatches | CDI Series
This is part two of a three part series in which we address how coders can better interact with Clinical Documentation Improvement (CDI) professionals. In this part, we discuss mismatches and how to best go about resolving them. In part three we will provide a case example of best practice interaction.
Part 1: How Coders Can Better Interact with CDI Teams | CDI Series
This is part one of a three part series in which we address how coders can better interact with Clinical Documentation Integrity (CDI) professionals. Many times these departments are separate and the remote environment makes it difficult to interact efficiently between the two departments. In part one, we will discuss the history and objectives of CDI so the coder has a better understanding of CDI’s role.
Coding Tip: Coding Diagnoses on Outpatient Encounters
One reason that coders should report chronic conditions (including history and status codes) on outpatient records is the HCC’s—Hierarchical Condition Categories. The quick and easy explanation of what HCC’s are is each HCC is mapped to certain ICD-10-CM codes or code ranges. HCC coding is designed to estimate future health care costs for patients.
Part 4: Top 5 ICD-10-CM Chapters 2019 | Acute Care Reviews
For Part 4 of this 5-part series, we will look at Chapter 10 within ICD-10-CM—J00-J99—Diseases of the Respiratory System. There is no possible way to include every guideline or coding reference for this chapter, but here are some of the most common issues.
Part 3: Top 5 ICD-10-CM Chapters 2019 | Acute Care Reviews
For Part 3 of this 5 part series, we will look at Chapter 9 within ICD-10-CM—I00-I99—Diseases of the Circulatory System. This chapter contains so many of the everyday diagnoses that we code such as hypertension, heart disease and stroke.
Part 2: Top 5 ICD-10-CM Chapters 2019 | Acute Care Reviews
For Part 2 of this 5-part series, we will look at Chapter 1 within ICD-10-CM—A00-B99—Certain Infectious and Parasitic Diseases. There is no possible way to include every guideline or coding reference for this chapter, but here are some of the most common issues.
Part 1: Top 5 ICD-10-CM Chapters 2019 | Acute Care Reviews
For Part 1 of this 5-part series, we will look at Chapter 21 within ICD-10-CM—Z00-Z99—Factors influencing health status and contact with health services. There is no possible way to include every guideline or coding reference for this chapter, but I’ll do my best to touch on some off the most common issues.
Coding & Quality Measures Tip: Social Determinants of Health
The HIM world has been buzzing recently with discussion of “Social Determinants of Health” and coded data. What does this mean for coders and the HIM field?
New ICD-10-CM Code for Vaping-Related Disorder
In response to the recent occurrences of vaping related disorders and in consultation with the World Health Organization (WHO) Framework Convention on Tobacco Control, the WHO Family of International Classifications (WHOFIC) Network Classification and Statistics Advisory Committee (CSAC) was convened to discuss a diagnosis code for vaping related illness for immediate use.